Cargando…
The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of the Coronavirus disease (COVID-19) pandemic, has so far resulted in more than 1.1 M deaths and 40 M cases worldwide with no confirmed remedy yet available. Since the first outbreak in Wuhan, China in December 2019,...
Autores principales: | Papageorgiou, Anastassios C., Mohsin, Imran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690584/ https://www.ncbi.nlm.nih.gov/pubmed/33105869 http://dx.doi.org/10.3390/cells9112343 |
Ejemplares similares
-
Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2
por: Prévost, Jérémie, et al.
Publicado: (2021) -
Identifying Hotspots in Binding of SARS-CoV-2 Spike Glycoprotein and Human ACE2
por: Mendis, Jenny, et al.
Publicado: (2021) -
Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM
por: Xu, Cong, et al.
Publicado: (2021) -
Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2
por: Shen, Min, et al.
Publicado: (2020) -
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein
por: Wrobel, Antoni G., et al.
Publicado: (2020)